Looking to publish in Cardiovascular Drugs and Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginCardiovascular Drugs and Therapy is dedicated to the development of cardiovascular drug, device, and cell therapy from bench to bedside. It focuses on advances in hyperlipidemia, diabetes and other cardiometabolic conditions, atherosclerosis, ischemic syndromes, heart failure, cardiomyopathies, valvular heart disease, arrhythmias, mechanisms of action and signaling pathways, new drug development, novel indications for older drugs, genetic approaches to treatment, and new directions in device and cell therapy, interventional and structural heart disease, and cardiac and vascular surgery, as well as guideline-based utilization in real-world patient populations.
Looking to publish in Cardiovascular Drugs and Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Existing customer loginSubmission Instructions
Cardiovascular Drugs and Therapy accepts the following article types. Click on an article type to view submission instructions.
Original Research Articles
Review Articles
Short Communications
Letters To The Editor
Recent Publications
Guideline-directed Low-density Lipoprotein Cholesterol Management After Acute Coronary Syndrome in Patients With Mental Illness: a Population-based Study
Yuval Avidan, Ofer Kobo, Baruch Weizman, Matan Jonas, Dana Hadar, Barak Zafrir, Sameer Kassem
Pericardial Extracellular Vesicles As Drug Carriers: Beyond Native Vesicle Therapy in Heart Failure
Le Wen, YuXin Sheng
Comparative Analysis of Antithrombotic Strategies Following Valve-in-Valve Transcatheter Aortic Valve Implantation Using Real-World Registry Data
Edward Dababneh, Maria Gabriela Matta, Ajay Sinhal, Selvanayagam Niranjan, Sylvio Provenzano, Anthony Camuglia, Ian Hughes, Kuljit Singh
Methodological Considerations Regarding “Impact of Nitric Oxide Metabolites on Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG”
Muhammad Shaheer Ahmad Baloch
Re: Effects of Dapagliflozin Combined with Sacubitril/Valsartan on Cardiac Electrophysiology and Quantitative Myocardial Motion Parameters in Patients with Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction
Ying Zhao
Frequently asked questions
How long does it take to publish?
All articles are reviewed by two or more referees. Accepted articles are published online after receipt of the corrected proofs.
Reformat to Cardiovascular Drugs and Therapy using Livewrite PremiumIs a cover letter required?
A submission letter is referenced for reviewer suggestions, unpublished material, and transparency on re-use of material.
Reformat to Cardiovascular Drugs and Therapy using Livewrite PremiumWhat are the publication costs?
Open access APC: £3090.00 GBP / $4690.00 USD / €3890.00 EUR. Subscription publishing has no APC charges.
Reformat to Cardiovascular Drugs and Therapy using Livewrite Premium